Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Ola Landgren, Benjamin Diamond, Abhishek Pandey, James Hoffman, David Coffey, Marcella Kaddoura, Brian Walker, Rabia Bukhari, Caterine Diaz, Stephanie Mompoint, Sindy Gutierrez, Kellye Koubek, Andrew Kowalski, Leslie Gallardo, Stephanie Fernandes, Sandra Mira, Massiel Cardo Lopez, Michelle Armogan, Dickran Kazandjian

Blood (2025) 146 (Supplement 1): 5775.

https://doi.org/10.1182/blood-2025-5775

Published: 2025

Journal Articles

Standardizing lines of treatment (LOT) in multiple myeloma: Real-world validation of an automated rule-based algorithm

Blood (2025) 146 (Supplement 1): 8154.

https://doi.org/10.1182/blood-2025-8154

Published: 2025

Journal Articles

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

Blood (2025) 146 (Supplement 1): 7479.

https://doi.org/10.1182/blood-2025-7479

Published: 2025

Journal Articles

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

Blood (2025) 146 (Supplement 1): 251.

https://doi.org/10.1182/blood-2025-251

Published: 2025

Journal Articles

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Blood (2025) 146 (Supplement 1): 248.

https://doi.org/10.1182/blood-2025-248

Published: 2025

Journal Articles

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response

Raffaella Cassano Cassano, Timothy Martins, David Coffey, Gabriele Buda, Sara Galimberti, Ryan Donnelly, Mary Kwok, Damian Green, Rahul Banerjee, Kara Cicero, Ted Gooley, Rebecca Silbermann, Pamela Becker, Andrew Cowan

Blood (2025) 146 (Supplement 1): 7446.

https://doi.org/10.1182/blood-2025-7446

Published: 2025

Journal Articles

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

Enze Liu, Nathan Becker, Sreejeta Mondal, Attaya Suvannasankha, David Coffey, Benjamin Diamond, Abhishek Pandey, Kelvin Lee, Dickran Kazandjian, Rafat Abonour, Aneta Mikulasova, Gareth Morgan, Ola Landgren, Brian Walker

Blood (2025) 146 (Supplement 1): 5693.

https://doi.org/10.1182/blood-2025-5693

Published: 2025

Journal Articles

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood (2025) 146 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2025-4052

Published: 2025

Journal Articles

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Ava Amidei, Benjamin Diamond, Elizabeth Lyubchenko, Stephanie Fernandes, Bahar Fard, Lubna Nousheen, Marc Arribas-Layton, Adam Sciambi, Dickran Kazandjian, James Hoffman, Abhishek Pandey, Marcella Kaddoura, Brian Walker, Ola Landgren, David Coffey

Blood (2025) 146 (Supplement 1): 2157.

https://doi.org/10.1182/blood-2025-2157

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Blood (2025) 146 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2025-3920

Published: 2025

Journal Articles

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Blood (2025) 146 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2025-4008

Published: 2025

Journal Articles

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Blood (2025) 146 (Supplement 1): 7483.

https://doi.org/10.1182/blood-2025-7483

Published: 2025

Journal Articles

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Benjamin Diamond, Niccolò Bolli, Paolo Corradini, David Coffey, Ola Landgren, Benedetto Bruno, Mario Boccadoro, Massimo Massaia, Francesco Maura, Alessandra Larocca

Blood (2023) 142 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2023-182301

Published: 2023

Journal Articles

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Andrew Kowalski, Jillian Lorayne Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman, Dickran Kazandjian, Ola Landgren

Blood (2023) 142 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2023-187086

Published: 2023

Journal Articles

Artificial Intelligence of the 2-D and 3-D Bone Marrow Microenvironment to Identify Cytogenetic Subtypes of Multiple Myeloma

Emilia O. Mason, David Coffey, Arjun Raj Rajanna, Abdessamad Youssfi Alaoui, Ekta Panjrolia, Dan Qu, Daniel Bilbao, Evan R. Roberts, Robert Diaz, Maria Laura Pascual, Francesco Maura, Jennifer R. Chapman-Fredricks, Ola Landgren

Blood (2023) 142 (Supplement 1): 7163.

https://doi.org/10.1182/blood-2023-188324

Published: 2023

Journal Articles

Impact of Gamma-Secretase Inhibition on the Multiple Myeloma Immune Microenvironment

David Coffey, Ola Landgren, Andrew J. Cowan, Pinar Ataca Atilla, Sylvain Simon, Margot Pont, Melissa L Comstock, Geoffrey R Hill, Stanley R. Riddell, Damian J Green

Blood (2023) 142 (Supplement 1): 4683.

https://doi.org/10.1182/blood-2023-186980

Published: 2023

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Blood (2022) 140 (Supplement 1): 430–432.

https://doi.org/10.1182/blood-2022-167390

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Standardizing lines of treatment (LOT) in multiple myeloma: Real-world validation of an automated rule-based algorithm

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Artificial Intelligence of the 2-D and 3-D Bone Marrow Microenvironment to Identify Cytogenetic Subtypes of Multiple Myeloma

Impact of Gamma-Secretase Inhibition on the Multiple Myeloma Immune Microenvironment

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only